EMAIL THIS PAGE TO A FRIEND

Oncogene

The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas.


PMID 23955078

Abstract

The incidence of skin cancer is increasing worldwide and cutaneous squamous cell carcinomas (SCCs) are associated with considerable morbidity and mortality, particularly in immunosuppressed individuals ('carcinomatous catastrophy'). Yet, molecular mechanisms are still insufficiently understood. Besides ultraviolet (UV)-indicative mutations, chromosomal aberrations are prominent. As telomeres are essential in preserving chromosome integrity, and telomere erosion as well as aberrant spatial telomere distribution contribute to genomic instability, we first established telomere length profiles across the whole tissue and identified normal skin (10/30) harboring discrete epidermal sites (stem cell territories) of evenly short telomeres. Precancerous actinic keratoses (AKs) (17) and SCCs (27) expressed two telomere phenotypes: (i) tissue-wide evenly short to intermediate and (ii) longer and tissue-wide heterogeneous telomere lengths, suggesting two modes of initiation, with one likely to originate in the epidermal stem cells. Although tumor histotype, location, patient gender or age failed to distinguish the two SCC telomere phenotypes, as did telomerase activity, we found a trend for a higher degree of aberrant p53 and cyclin D1 expression with long/heterogeneous telomeres. In addition, we established an association for the short/homogeneous telomeres with a simpler and the heterogeneous telomeres with a more complex karyotype correlating also with distinct chromosomal changes. SCCs (13) from renal transplant recipients displayed the same telomere dichotomy, suggesting that both telomere subtypes contribute to 'carcinomatous catastrophy' under immunosuppression by selecting for a common set (3, 9p and 17q) and subtype-specific aberrations (e.g., 6p gain, 13q loss). As a second mechanism of telomere-dependent genomic instability, we investigated changes in telomere distribution with its most severe form of telomeric aggregates (TAs). We identified a telomere length-independent but progression-dependent increase in cells with small telomere associations in AKs (17/17) and additional TAs in SCCs (24/32), basal cell carcinomas (30/31) and malignant melanomas (15/15), and provide evidence for a reactive oxygen species-dependent mechanism in this UV-induced telomere organization-dependent genomic instability.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1306667
ANTI-P53 (S15) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1306713
ANTI-P53 (S315) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1306623
ANTI-P53 (SUMOYLATION SITE SPECIFIC) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
P4235 Anti-p53 antibody produced in sheep, fractionated antiserum, buffered aqueous solution
SAB4300365
Anti-TP53 (Ab-18) antibody produced in rabbit, affinity isolated antibody
SAB4300369
Anti-TP53 (Ab-315) antibody produced in rabbit, affinity isolated antibody
SAB4300366
Anti-TP53 (Ab-33) antibody produced in rabbit, affinity isolated antibody
SAB4300367
Anti-TP53 (Ab-37) antibody produced in rabbit, affinity isolated antibody
SAB4300368
Anti-TP53 (Ab-46) antibody produced in rabbit, affinity isolated antibody
SAB4300362
Anti-TP53 (Ab-6) antibody produced in rabbit, affinity isolated antibody
SAB4300363
Anti-TP53 (Ab-9) antibody produced in rabbit, affinity isolated antibody
SAB2102511
Anti-TP53 (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2102512
Anti-TP53 (ab2) antibody produced in rabbit, affinity isolated antibody
SAB2102513
Anti-TP53 (ab3) antibody produced in rabbit, affinity isolated antibody
SAB2102514
Anti-TP53 (ab4) antibody produced in rabbit, affinity isolated antibody
SAB2102515
Anti-TP53 (ab5) antibody produced in rabbit, affinity isolated antibody
SAB1406544
Anti-TP53 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV02055
Anti-TP53 antibody produced in rabbit, IgG fraction of antiserum
AV37163
Anti-TRP53 antibody produced in rabbit, IgG fraction of antiserum
SAB2106418
Anti-TRP53 antibody produced in rabbit, affinity isolated antibody
P6749
Monoclonal Anti-p53 antibody produced in mouse, clone PAb1801, purified from hybridoma cell culture
AMAB90956
Monoclonal Anti-p53 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL2199, purified immunoglobulin, buffered aqueous glycerol solution
P5813
Monoclonal Anti-p53 antibody produced in mouse, clone BP53-12, ascites fluid
P8999
Monoclonal Anti-p53 antibody produced in mouse, clone DO-7, purified from hybridoma cell culture
P7874 Monoclonal Anti-p53 antibody produced in mouse, ~2 mg/mL, clone DO-2, purified immunoglobulin, buffered aqueous solution
P6874
Monoclonal Anti-p53 antibody produced in mouse, clone DO-1, purified from hybridoma cell culture
WH0007157M1
Monoclonal Anti-TP53 antibody produced in mouse, clone 2C3, purified immunoglobulin, buffered aqueous solution
SAB1404483
Monoclonal Anti-TP53 antibody produced in mouse, clone 2C11, purified immunoglobulin, buffered aqueous solution
PLA0072
Rabbit anti-p53 Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.